Needham & Company Starts Geron Corporation (GERN) at Hold; Six Ongoing Studies, But Outcome Hard to Predict

Article Stock Quotes (1) Comments (0)

Needham & Company initiates coverage on Geron Corporation (NASDAQ: GERN) with a Hold.

Analyst, Chad Messer, said, "Geron has $137 million ($1.06/share) in cash which we are confident is more than required to complete the 6 ongoing studies and devise a registrational path (assuming there is one) for both drugs. However, we do not feel compelled to chase GERN shares without further clinical data and a more defined clinical path for its 2 programs."

For an analyst ratings summary and ratings history on Geron Corporation click here. For more ratings news on Geron Corporation click here.

Shares of Geron Corporation closed at $1.76 yesterday, with a 52 week range of $1.25-$4.39.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Wells Fargo Starts Popular, Inc. (BPOP) at Outperform
• Best Buy (BBY) Numbers Raised at Jefferies Post Q1
• BMO Capital Starts Verisk Analytics (VRSK) at Outperform

Create E-mail Alert Related Categories

New Coverage

Related Entities

Needham & Company

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?